Bortezomib is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.It was originally synthesized in 1995 at Myogenics and was approved in the United States by the FDA for use in multiple myeloma in May 2003.

we manufacture and provide the key intermediate (779357-85-6),white powder solid,

the purity is more than 99%(GC).

top quality, more competitive price.

 NMR,GC,IR,MOA,COA are available.

The minimum order quantity is 50 Grams,

Special packing is offered.